TerSera is expected to pay us $40 million at closing, and we may receive additional sales milestone payments of up to an aggregate of $35 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. We expect to pay an $8 million amendment fee to our current commercialization partner during the fourth quarter of 2024 and will manufacture MARGENZA drug substance on behalf of TerSera going forward. The pending margetuximab transaction, as well as the recently received $100 million in milestones from Incyte, further strengthen our financial position, enabling us to sharpen our focus on our key priorities of advancing our clinical-stage assets while researching and developing the next wave of early stage product candidates.